BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Crisugabalin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Crisugabalin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06766916-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Crisugabalin: Phase 2 readout est. (NCT06766916)
DESCRIPTION:Crisugabalin\, phase 2.\nStudy: Crisugabalin for Radiotherapy-R
 elated Neuropathic Pain\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/crisugabalin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06766916
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330648-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Crisugabalin: Phase 2 readout est. (NCT07330648)
DESCRIPTION:Crisugabalin\, phase 2.\nStudy: Prospective Clinical Trial of C
 risugabalin Capsules in the Treatment of Generalized Anxiety Disorder\nEst
 imated primary completion: 31 January 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/crisugabalin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07330648
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453862-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Crisugabalin: Phase 1 readout est. (NCT07453862)
DESCRIPTION:Crisugabalin\, phase 1.\nStudy: Novel Calcium Channel Modulator
 s in RLS and Variants: Efficacy & Safety\nEstimated primary completion: 30
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/crisugaba
 lin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07453862
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196657-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Crisugabalin: Phase na readout est. (NCT07196657)
DESCRIPTION:Crisugabalin\, phase na.\nStudy: The Efficacy and Safety of Pre
 gabalin and Crisugabalin in Patients With Fibromyalgia\nEstimated primary 
 completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/crisugabalin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07196657
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422117-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Crisugabalin: Phase 3 readout est. (NCT06422117)
DESCRIPTION:Crisugabalin\, phase 3.\nStudy: Efficacy and Safety of HSK16149
  Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain 
 in China\nEstimated primary completion: 30 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/crisugabalin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06422117
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483398-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Crisugabalin: Phase 4 readout est. (NCT07483398)
DESCRIPTION:Crisugabalin\, phase 4.\nStudy: EFficacy and safEty of cRisugab
 alin on nocipLastic paIn in Patients With Parkinson's Disease (RELIEF-PD):
  a Multicentre\, Double-blind\, Randomised Controlled Trial\nEstimated pri
 mary completion: 15 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/crisugabalin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07483398
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307976-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Crisugabalin: Phase na readout est. (NCT07307976)
DESCRIPTION:Crisugabalin\, phase na.\nStudy: The Analgesic Efficacy and Saf
 ety of Crisugabalin in Patients With Herpes Zoster\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/crisugabalin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07307976
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699770-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Crisugabalin: Phase 4 readout est. (NCT07699770)
DESCRIPTION:Crisugabalin\, phase 4.\nStudy: Crisugabalin in NMOSD Neuropath
 ic Pain: A Randomized\, Double-Blind\, Placebo-Controlled Exploratory Tria
 l\nEstimated primary completion: 31 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/crisugabalin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07699770
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859111-8791@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Crisugabalin: Phase 3 readout est. (NCT07859111)
DESCRIPTION:Crisugabalin\, phase 3\, Diabetic Peripheral Neuropathic Pain.\
 nStudy: YJ001 Spray for Diabetic Peripheral Neuropathic Pain\nEstimated pr
 imary completion: 30 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crisugabalin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07859111
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
